Cargando…

The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models

SIMPLE SUMMARY: Considering recent research, it was established that the best experimental models to conserve biological features of human tumors and to predict individual clinical treatment success are patient-derived xenografts (PDX). Their recognized and growing importance for translational resea...

Descripción completa

Detalles Bibliográficos
Autores principales: Matschos, Stephanie, Bürtin, Florian, Kdimati, Said, Radefeldt, Mandy, Krake, Susann, Prall, Friedrich, Engel, Nadja, Krohn, Mathias, Micheel, Bianca, Kreutzer, Michael, Mullins, Christina Susanne, Linnebacher, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656526/
https://www.ncbi.nlm.nih.gov/pubmed/34884989
http://dx.doi.org/10.3390/cancers13235882
_version_ 1784612302246379520
author Matschos, Stephanie
Bürtin, Florian
Kdimati, Said
Radefeldt, Mandy
Krake, Susann
Prall, Friedrich
Engel, Nadja
Krohn, Mathias
Micheel, Bianca
Kreutzer, Michael
Mullins, Christina Susanne
Linnebacher, Michael
author_facet Matschos, Stephanie
Bürtin, Florian
Kdimati, Said
Radefeldt, Mandy
Krake, Susann
Prall, Friedrich
Engel, Nadja
Krohn, Mathias
Micheel, Bianca
Kreutzer, Michael
Mullins, Christina Susanne
Linnebacher, Michael
author_sort Matschos, Stephanie
collection PubMed
description SIMPLE SUMMARY: Considering recent research, it was established that the best experimental models to conserve biological features of human tumors and to predict individual clinical treatment success are patient-derived xenografts (PDX). Their recognized and growing importance for translational research, especially for late-stage preclinical testing of novel therapeutics, necessitates a high number of well-defined PDX models from individual patients’ tumors. The starting platform for the Hansestadt Rostock colorectal cancer (HROC)-Xenobank was the assortment of colorectal tumor and normal tissue samples from patients stored in our university biobank. ABSTRACT: Based on our research group’s large biobank of colorectal cancers (CRC), we here describe the ongoing activity of establishing a high quality assured PDX biobank for more than 100 individual CRC cases. This includes sufficient numbers of vitally frozen (n > 30 aliquots) and snap frozen (n > 5) backups, “ready to use”. Additionally, PDX tumor pieces were paraffin embedded. At the current time, we have completed 125 cases. This resource allows histopathological examinations, molecular characterizations, and gene expression analysis. Due to its size, different issues of interest can be addressed. Most importantly, the application of low-passage, cryopreserved, and well-characterized PDX for in vivo studies guarantees the reliability of results due to the largely preserved tumor microenvironment. All cases described were molecularly subtyped and genetic identity, in comparison to the original tumor tissue, was confirmed by fingerprint analysis. The latter excludes ambiguity errors between the PDX and the original patient tumor. A cancer hot spot mutation analysis was performed for n = 113 of the 125 cases entities. All relevant CRC molecular subtypes identified so far are represented in the Hansestadt Rostock CRC (HROC)-Xenobank. Notably, all models are available for cooperative research approaches.
format Online
Article
Text
id pubmed-8656526
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86565262021-12-10 The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models Matschos, Stephanie Bürtin, Florian Kdimati, Said Radefeldt, Mandy Krake, Susann Prall, Friedrich Engel, Nadja Krohn, Mathias Micheel, Bianca Kreutzer, Michael Mullins, Christina Susanne Linnebacher, Michael Cancers (Basel) Article SIMPLE SUMMARY: Considering recent research, it was established that the best experimental models to conserve biological features of human tumors and to predict individual clinical treatment success are patient-derived xenografts (PDX). Their recognized and growing importance for translational research, especially for late-stage preclinical testing of novel therapeutics, necessitates a high number of well-defined PDX models from individual patients’ tumors. The starting platform for the Hansestadt Rostock colorectal cancer (HROC)-Xenobank was the assortment of colorectal tumor and normal tissue samples from patients stored in our university biobank. ABSTRACT: Based on our research group’s large biobank of colorectal cancers (CRC), we here describe the ongoing activity of establishing a high quality assured PDX biobank for more than 100 individual CRC cases. This includes sufficient numbers of vitally frozen (n > 30 aliquots) and snap frozen (n > 5) backups, “ready to use”. Additionally, PDX tumor pieces were paraffin embedded. At the current time, we have completed 125 cases. This resource allows histopathological examinations, molecular characterizations, and gene expression analysis. Due to its size, different issues of interest can be addressed. Most importantly, the application of low-passage, cryopreserved, and well-characterized PDX for in vivo studies guarantees the reliability of results due to the largely preserved tumor microenvironment. All cases described were molecularly subtyped and genetic identity, in comparison to the original tumor tissue, was confirmed by fingerprint analysis. The latter excludes ambiguity errors between the PDX and the original patient tumor. A cancer hot spot mutation analysis was performed for n = 113 of the 125 cases entities. All relevant CRC molecular subtypes identified so far are represented in the Hansestadt Rostock CRC (HROC)-Xenobank. Notably, all models are available for cooperative research approaches. MDPI 2021-11-23 /pmc/articles/PMC8656526/ /pubmed/34884989 http://dx.doi.org/10.3390/cancers13235882 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Matschos, Stephanie
Bürtin, Florian
Kdimati, Said
Radefeldt, Mandy
Krake, Susann
Prall, Friedrich
Engel, Nadja
Krohn, Mathias
Micheel, Bianca
Kreutzer, Michael
Mullins, Christina Susanne
Linnebacher, Michael
The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models
title The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models
title_full The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models
title_fullStr The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models
title_full_unstemmed The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models
title_short The HROC-Xenobank—A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models
title_sort hroc-xenobank—a high quality assured pdx biobank of >100 individual colorectal cancer models
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656526/
https://www.ncbi.nlm.nih.gov/pubmed/34884989
http://dx.doi.org/10.3390/cancers13235882
work_keys_str_mv AT matschosstephanie thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT burtinflorian thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT kdimatisaid thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT radefeldtmandy thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT krakesusann thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT prallfriedrich thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT engelnadja thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT krohnmathias thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT micheelbianca thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT kreutzermichael thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT mullinschristinasusanne thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT linnebachermichael thehrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT matschosstephanie hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT burtinflorian hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT kdimatisaid hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT radefeldtmandy hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT krakesusann hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT prallfriedrich hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT engelnadja hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT krohnmathias hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT micheelbianca hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT kreutzermichael hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT mullinschristinasusanne hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels
AT linnebachermichael hrocxenobankahighqualityassuredpdxbiobankof100individualcolorectalcancermodels